The aim of the study was to assess the efficacy and safety of rituximab (RTX) for treating systemic lupus erythematosus (SLE)-associated immune cytopenias. This multicenter retrospective cohort study of adults from French referral centers and networks for adult immune cytopenias and SLE involved patients 18 years old with a definite diagnosis of SLE treated with RTX specifically for SLE-associated immune cytopenia from 2005 to 2015. Response assessment was based on standard definitions. In total, 71 patients, 61 women (85.9%), with median age 36 years [interquartile range 31-48], were included. The median duration of SLE at the time of the first RTX administration was 6.1 years [2.6-11.6] and the reason for using RTX was immune thrombocytopenia (ITP) for 44 patients (62.0%), autoimmune hemolytic anemia (AIHA) for 16 (22.5%), Evans syndrome for 10 (14.1%), and pure red cell aplasia for one patient. Before receiving RTX, patients had received a mean of 3.1 6 1.3 treatments that included corticosteroids (100%), and hydroxychloroquine (88.5%). The overall initial response rate to RTX was 86% (91% with ITP, 87.5% with AIHA, and 60% with Evans syndrome), including 60.5% with complete response. Median follow-up after the first injection of RTX was 26.4 months [14.3-71.2]. Among 61 initial responders, relapse occurred in 24 (39.3%); for 18, RTX retreatment was successful in 16 (88.8%). Severe infections occurred after RTX in three patients, with no fatal outcome. No cases of RTX-induced neutropenia were observed. In conclusion, RTX seems effective and relatively safe for treating SLE-associated immune cytopenias.
| I N TR ODU C TI ON
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by B-cell activation with production of pathogenic autoantibodies and deposition of immune complexes in various organs. Immune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA) are relatively common hematologic manifestations of SLE occurring in approximately 20% and 5% of SLE patients. 1 Conversely, SLE represents approximately 5% of all ITP cases in adults 2 and is the leading cause of secondary warm AIHA among young women. 3 Primary ITP, and presumably also SLE-associated ITP, 4 results from accelerated platelet destruction and impaired platelet production mainly mediated by autoantibodies targeting glycoproteins expressed on platelet and megakaryocytes. AIHA is characterized by a shortened lifespan and accelerated destruction of mature red blood cells caused by immunoglobulin G (IgG) and/or complement bound to the surface of red blood cells detected by the direct antiglobulin test (DAT). Both cytopenias may seldom occur simultaneously or sequentially in the same patient, which defines Evans syndrome. 5 Corticosteroids are the cornerstone of treatment for SLEassociated ITP and/or AIHA, and prednisone (or prednisolone) is given, at the initial daily dose of 1 mg/kg or even more. As for primary ITP, for SLE-associated ITP with significant bleeding (i.e., mucosal bleeding), intravenous Ig (IVIg) can be given with corticosteroids.
However, for many patients with SLE-associated immune cytopenias requiring treatment, relapse is common when prednisone is tapered or stopped, which requires the use of other treatment lines. 6 In a few retrospective studies, hydroxychloroquine (HCQ) showed potential benefit as a corticosteroid-sparing agent for treating SLEassociated ITP, 7 but we have no comparable data for SLE-associated AIHA.
Rituximab (RTX), a chimeric murine/human anti-CD20 monoclonal antibody, is frequently used off-label in many countries as second-line therapy for adult primary immune cytopenias; indeed, a number of prospective and randomized studies reported its efficacy, with an overall response-rate at 1 year of 50% to 60% for ITP 8 and 75% for warm AIHA. 9 Regarding efficacy of RTX in renal and extra- of cases, with a corticosteroid-sparing effect and a good safety profile. 13 The literature contains limited data suggesting that RTX is a good option for treating SLE-associated immune cytopenias. 14 Hence, the aim of the present study was to better evaluate the long-term efficacy and safety of RTX for patients with SLE-associated immune cytopenias. 
| P A TI EN TS A N D M ETH OD S

| Response criteria
Response was evaluated 3 months after the first RTX infusion. For SLE-associated ITP, response criteria were the same as those commonly used for primary ITP at least a 20 g/L increase from the pretreatment level. 16 CR and PR were retained only for patients who received corticosteroids and/or other immunosuppressive agents at a stable or decreasing dose.
Among the responders, relapse was defined as the loss of CR or PR criteria during follow-up.
| Safety
Reported laboratory or clinical adverse events presumably caused by RTX were collected and graded according to the US National Cancer
Institute Common Terminology Criteria (NCICTC) v4.0. Taking into account the duration of action of RTX, severe infection was defined as an infection occurring within the 12 months after RTX infusion (initial treatment or retreatment) and requiring hospitalization and/or intravenous antibiotics and/or resulting in death. 
| Statistical analysis
| Ethical considerations
The study was performed in accordance with the ethical standards of the Helsinki Declaration and was approved by our local IRB. 
| Efficacy
Initial OR after RTX treatment and the modalities of RTX administration are summarized in 
| Treatment failure
Among the 10 patients with no response to RTX, 2 had retreatment with RTX: response was observed in one patient with incomplete Bcell depletion after the first RTX treatment. Three patients underwent splenectomy (3 CR) and 4 received an immunosuppressive agent (2 CR). Data were not available for one patient.
| Safety
Every patient received 100 mg of i.v methylprednisolone and 100 mg of diphenhydramine chlorhydrate as a premedication before each RTX administration. We observed seven (9.9%) mild (grade 1) to moderate (grade 2) acute infusion reactions (including fever, hypotension, myalgia, skin rash). Some data regarding serum gammaglobulin levels at least 
| D ISC USSION
In the present study, we report data on the efficacy and safety of RTX for treating SLE-associated autoimmune cytopenias from an analysis of a large retrospective cohort of patients. In keeping with some previous studies reporting the potential efficacy of RTX in SLE 12 , our study found RTX with a good risk/benefit ratio for treating adult patients with active SLE-associated autoimmune cytopenias. The overall initial response rate to RTX was 86%, including 60.5% CR, and the rate of initial CR observed in lupus-associated ITP and AIHA were similar to that observed in primary ITP and primary warm AIHA, respectively. 8, 9 Furthermore, 32% of the initial responders with treatment for ITP and 62.5% of responders with treatment for AIHA showed sustained response lasting at least 2 years. This finding agrees with other studies reporting that 40% and 21% of adults with chronic primary ITP treated with RTX maintained a treatment-free response after 2 and 5 years, respectively. 18, 19 In the RAIHA study, 62.5% of the patients with AIHA still showed CR at 2 years. 9 Among patients with an initial response in the present study, almost 40% experienced relapse during follow-up, which required retreatment with RTX or intravenous pulses of methylprednisolone. We could not identify any clinical or laboratory factor that predicted relapse among initial responders, but retreatment with RTX for ITP or AIHA relapse led to 100% secondary response. In contrast to a common practice for rheumatoid arthritis and systemic vasculitis, in the absence of predicting markers of relapse, a maintenance therapy with RTX every 6 to 12 months to avoid relapse with SLEassociated ITP or AIHA cannot be recommended. In the absence of initial response to RTX or in case of early relapse, splenectomy can be a safe an effective option in the absence of severe extra-hematological manifestations and overt associated antiphosholipid syndrome. 20 Another potential option to enhance the rate of durable responses could be a combination strategy with RTX 1 dexamethasone or the sequential use of RTX followed by belimumab. 21, 22 Indeed, the spleen of ITP patients treated with rituximab contained an excess of the cytokine BAFF which, in in vitro cultures of splenic cells, could increase the longevity of plasma cells 21 and a very rapid increase of the levels of BAFF in the peripheral blood have been shown after RTX in SLE. 22 The safety of RTX was acceptable: only 9.9% of patients experienced adverse events, mainly mild-to-moderate infusion reactions. This rate could be explained in part by the effect of methylprednisolone (100 mg intravenously) administered systematically just before each RTX administration as premedication to reduce infusion-related reactions.
The incidence rate of severe infections (1.2/100 patient-years) was lower than that found in the EXPLORER study or in the AIR registry (6.6/100 patient-years). This difference might be related to the low proportion of patients in our study receiving, beyond corticosteroids, concomitant immunosuppressive agents such as mycophenolate mofetil or azathioprine (19.7% as compared with 100% in the EXPLORER study and 52% in the AIR registry). Beyond severe infections, the exact incidence rate of secondary hypogammaglobulinemia could not be calculated as data were available only for 44% of the patients (estimated rate 9 per 100 patients-year).
The limitations of the study are mostly its retrospective design, which can be a source of selection bias; some data were not available and a few patients were lost to follow-up. These limitations preclude concluding on the analysis of gammaglobulin levels, the level of B-cell depletion after RTX, the accuracy of the prednisone-sparing effect of RTX assessment and the rapidity of response after B-cell depletion.
Moreover, the effect of RTX on the need for concomitant immunosuppressive drugs and corticosteroids was difficult to assess because most patients receiving an immunosuppressant had other nonhematogical lupus manifestations with organ involvement requiring long-term treatment.
In conclusion, this study shows that RTX given off-label has good efficacy and safety profile for treating SLE-associated immune cytopenias. The response can be durable and in cases of relapse, retreatment with RTX is feasible and effective. Although RTX is not licensed for SLE, its off-label use should be considered, whenever possible, before splenectomy for patients with corticosteroid-dependent ITP and/or AIHA as the leading manifestations of SLE.
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